UK: Lifesciences Snapshot: Summer 2008

Bringing you quarterly news of key developments of relevance to the Lifesciences sector.


London Agreement entered into force on 1 May

Following the deposit by France of the instrument of ratification with the German Ministry of Justice on 29 January, the London Agreement entered into force on 1 May 2008. The London Agreement is an amendment to the European Patent Convention that simplifies the language regime, largely or entirely waiving the need for translations of granted European patents. Countries such as the United Kingdom, France or Germany whose national language is also an official EPO language will dispense with translation requirements altogether. It is hoped that the reduction in costs will encourage small and medium-sized enterprises to pursue patent protection.

Actavis UK Limited -v- Merck & Co Inc [2008] EWCA Civ 444

The Court of Appeal has ruled that a Swiss form claim for the use of a pharmaceutical in the manufacture of a medicament could be allowed even where the novelty lay only in a new dosing regime. Emphasising the importance of taking an approach consistent with that of the EPO, the Court rejected arguments that it was bound not to allow such a claim on the basis of the Court of Appeal judgment in Bristol-Myers Squibb v Baker Norton.

The case is likely to be of great interest to the pharmaceutical industry, as it provides a more consistent approach to patentability of Swiss claims across the European Patent Convention countries, and will improve the prospects of pharmaceutical companies seeking to obtain patent protection in the UK for new applications of known substances.

For our full Law-Now on this decision, click here.

T 1319/04 - 3.3.02 Dosage regimen/KOS LIFE SCIENCES, INC. (EPO Board of Appeal)

The European Patent Office Board of Appeal has referred two questions concerning the interpretation of the "second medical use" provisions of the EPC 2000 as introduced in December last year. Specifically, whether it was possible to patent a medicament which is already known for treatment of the same illness where the only novel aspect is the new method of treatment / dosing.

For the full text of the decision, click here.

Government response to the EC's consultation on counterfeit medicines for human use

In March 2008, the European Commission released a public consultation on proposals for tackling counterfeit medicines. The Commission were of the opinion that the rise in counterfeit medicines has been caused by uncertainty as to the subjects of pharmaceutical legislation and guidance, shortcomings in product integrity and lack of compliance with pharmaceutical legislation and guidance. For a full copy of the public consultation, click here.

The UK government response to the European Commission's consultation on counterfeit medicines for human use was published in May 2008. In general, the UK government supported the Commission's proposals, although it asked for further information on how the proposed schemes would operate in practice. The government commented that the requirements of a unique packaging seal from the manufacturer and a ban on repackaging could prevent importers from complying with leaflet and labelling provisions. The government also expressed concern that proposals, in particular the proposal for a centrally accessible record system, could place too heavy a burden on the healthcare profession, especially if the adopted system is incompatible with national systems. For the government's full response, click here.


Regulation of NHS Advertisements

A Code of Practice for the Promotion of NHS-Funded Services has been issued to regulate the advertising of NHS-funded services. The new Code requires all providers of NHS-funded services to comply with applicable Advertising Standards Authority Codes and additional NHS-specific rules. The purpose is to ensure that patients have accurate information so that they can make effective choices and receive treatment that best fits their individual needs.

The Code applies to all providers of NHS-commissioned services whether independent sector, NHS providers or charities. It also applies to the entire range of promotional activity undertaken by providers of NHS-funded services, including advertising, direct marketing to patients and information directed at referring clinicians. In addition, it is intended to regulate the level of expenditure on promotional activity by requiring open disclosure of this by providers.

Enforcement of the Code will be split. Marketing communications already covered by the Advertising Codes will remain under the existing ASA regime. Complaints under the NHS-specific rules will be administered by the relevant commissioning Primary Care Trust and/or the Strategic Health Authority.

The Code sets out general principles and contains specific rules covering NHS brand/reputation protection; direct marketing to public and referring clinicians; claim substantiation and comparative claims; service providers' representatives; promotional expenditure; gifts and inducements to clinicians and commissioners as well as the public; testimonials and endorsements; sponsorship; compliance with undertakings and complaints and enforcement.

For the full Law-Now article on this click here.

Stock management of pharmaceuticals

Advocate General Ruiz-Jarabo's opinion in a case involving GlaxoSmithKline's (GSK) stock management policy of certain drugs in Greece was released on 1 April 2008. GSK's policy limited quantities of products sold to wholesalers to levels sufficient to meet the needs of the Greek market. GSK was clear that the policy was intended to limit the levels of parallel trade from Greece. Wholesalers claimed that this policy was an abuse of dominant position under Article 82 EC Treaty. Taking a tough stance towards GSK and the pharmaceutical innovator in general, AG Ruiz-Jarabo considers that a restriction of supply by a dominant pharmaceutical company in order to limit parallel trade can in principle be a breach of Article 82 EC Treaty. He does not accept that the restriction may be justified due to the negative impact of parallel trade on GSK's incentives to innovate. It remains to be seen whether the ECJ will follow this opinion.

For the full Law-Now article on this click here.


New UK law of fair dealing

Two sets of UK Regulations came into force on 26 May 2008, implementing the EC Unfair Commercial Practices Directive (2005/29/EC). These are the Consumer Protection from Unfair Trading Regulations 2008 (SI 2008/1277 – "CPRs") and the Business Protection from Misleading Marketing Regulations 2008 (SI 2008/1276 – "BPRs").

Under the CPRs, unfair commercial practices are prohibited. A practice is unfair if it is a misleading action, a misleading omission, an aggressive commercial practice or is a practice listed in schedule 1 of the CPRs.

The BPRs regulate unfair business-to-business practices in the UK. The Regulations do not alter businesses' obligations not to use advertisements that mislead other businesses. The main change from the previous legislation is that the rules apply to "indications" and not merely traditional advertising.

For the full Law-Now article on this click here.

This article was written for Law-Now, CMS Cameron McKenna's free online information service. To register for Law-Now, please go to

Law-Now information is for general purposes and guidance only. The information and opinions expressed in all Law-Now articles are not necessarily comprehensive and do not purport to give professional or legal advice. All Law-Now information relates to circumstances prevailing at the date of its original publication and may not have been updated to reflect subsequent developments.

The original publication date for this article was 29/07/2008.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions